The object of the present invention is the combination of palmitoylethanolamide (PEA) and lycopene and/or pharmaceutically acceptable salts and/or derivatives thereof the pharmaceutical formulations comprising the combination of PEA and lycopene and/or pharmaceutically acceptable salts or derivatives thereof optionally together with at least one pharmacologically acceptable excipient and the use of the combination of PEA and lycopene and/or pharmaceutically acceptable salts or derivatives thereof and of the formulations comprising such a combination in the treatment of inflammatory diseases.
